肝硬化门静脉高压症的肝移植治疗

摘要/Abstract

中图分类号:

R657.34

李涛, 陈皓. 肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.

LI Tao, CHEN Hao. Liver transplantation in treatment of cirrhotic portal hypertension[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 189-194.

图/表1

参考文献32

[33]	Ng CK, Chan MH, Tai MH, et al. Hepatorenal syndrome[J]. Clin Biochem Rev, 2007, 28(1):11-17.
[34]	Terra C, Mattos ÂZ, Pereira G, et al. Recommendations of the Brazilian Society of Hepatology for the management of acute kidney injury in patients with cirrhosis[J]. Arq Gastroenterol, 2018, 55(3):314-320. doi:10.1590/s0004-2803.201800000-71 URL
[35]	Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(2):162-177. doi:10.1016/j.cgh.2017.05.041 URL
[36]	Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation[J]. Hepatology, 2005, 41(6):1282-1289. pmid:15834937
[37]	Utako P, Emyoo T, Anothaisintawee T, et al. Clinical outcomes after liver transplantation for hepatorenal syndrome: a systematic review and meta-analysis[J]. Biomed Res Int, 2018, 2018:5362810.
[38]	Wong F, Leung W, Al Beshir M, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation[J]. Liver Transpl, 2015, 21(3):300-307. doi:10.1002/lt.24049 URL
[39]	Francoz C, Durand F, Kahn JA, et al. Hepatorenal syndrome[J]. Clin J Am Soc Nephrol, 2019, 14(5):774-781. doi:10.2215/CJN.12451018 URL
[40]	Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020, 16(3):137-155. doi:10.1038/s41581-019-0218-4 URL
[41]	Razavi-Khorasani N, Moazzami B, Dooghaie Moghadam A, et al. Pulmonary complications in candidates for liver transplantation[J]. Middle East J Dig Dis, 2020, 12(3):145-153. doi:10.34172/mejdd.2020.176 URL
[42]	Goldberg DS, Krok K, Batra S, et al. Impact of the he-patopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database[J]. Gastroenterology, 2014, 146(5):1256-1265. doi:10.1053/j.gastro.2014.01.005pmid:24412528
[43]	Cywinski JB, Makarova N, Arney A, et al. Resources utilization after liver transplantation in patients with and without hepatopulmonary syndrome: Cleveland Clinic experience[J]. Transplant Direct, 2020, 6(4):e545. doi:10.1097/TXD.0000000000000990 URL
[44]	Schenk P, Schöniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis[J]. Gastroenterology, 2003, 125(4):1042-1052. pmid:14517788
[45]	Gupta S, Krowka MJ. Hepatopulmonary syndrome[J]. CMAJ, 2018, 190(8):E223. doi:10.1503/cmaj.170253 URL
[46]	Iyer VN, Swanson KL, Cartin-Ceba R, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era[J]. Hepatology, 2013, 57(6):2427-2435. doi:10.1002/hep.26070 URL
[47]	Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm[J]. Hepatology, 2006, 44(6):1502-1510. doi:10.1002/hep.21431 URL
[48]	Cartin-Ceba R, Krowka MJ. Pulmonary complications of portal hypertension[J]. Clin Liver Dis, 2019, 23(4):683-711. doi:S1089-3261(19)30042-Xpmid:31563218
[49]	Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups[J]. Am J Transplant, 2008, 8(11):2445-2453. doi:10.1111/j.1600-6143.2008.02384.xpmid:18782292
[50]	Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation[J]. Liver Transpl, 2000, 6(4):443-450. doi:10.1053/jlts.2000.6356 URL
[51]	Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation, 2016, 100(7):1440-1452. doi:10.1097/TP.0000000000001229 URL
[52]	Raevens S, Colle I, Reyntjens K, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values[J]. Liver Transpl, 2013, 19(6):602-610. doi:10.1002/lt.23649 URL
[53]	Lasch HM, Fried MW, Zacks SL, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome[J]. Liver Transpl, 2001, 7(2):147-149. doi:10.1053/jlts.2001.21287 URL
[54]	Huang L, Yu QS, Zhang Q, et al. Transjugular intrahe-patic portosystemic shuntversussurgical shunting in the management of portal hypertension[J]. Chin Med J (Engl), 2015, 128(6):826-834.
[55]	Henderson JM. Surgical treatment of portal hypertension[J]. Baillieres Best Pract Res Clin Gastroenterol, 2000, 14(6):911-925. pmid:11139346
[56]	Chen H, Turon F, Hernández-Gea V, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation[J]. Liver Transpl, 2016, 22(3):352-365. doi:10.1002/lt.24387 URL
[57]	Violi F, Corazza GR, Caldwell SH, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry[J]. Intern Emerg Med, 2016, 11(8):1059-1066. doi:10.1007/s11739-016-1416-8 URL
[58]	Stine JG, Shah PM, Cornella SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis[J]. World J Hepatol, 2015, 7(27):2774-2780. doi:10.4254/wjh.v7.i27.2774 URL
[59]	D'amico G, de Franchis R. Upper digestive bleeding in cirrhosis. post-therapeutic outcome and prognostic indicators[J]. Hepatology, 2003, 38(3):599-612.
[60]	Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: a challenging consequence of li-ver cirrhosis[J]. J Clin Transl Hepatol, 2020, 8(4):432-444. doi:10.14218/JCTH.2020.00067pmid:33447527
[61]	Zanetto A, Rodriguez-Kastro KI, Germani G, et al. Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis[J]. Transpl Int, 2018, 31(12):1318-1329. doi:10.1111/tri.13353 URL
[62]	Vianna RM, Mangus RS, Kubal C, et al. Multivisceral transplantation for diffuse portomesenteric thrombosis[J]. Ann Surg, 2012, 255(6):1144-1150. doi:10.1097/SLA.0b013e31825429c0 URL
[1]	de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis[J]. Clin Liver Dis, 2001, 5(3):645-663. pmid:11565135
[2]	Hackl C, Schlitt HJ, Renner P, et al. Liver surgery in cirrhosis and portal hypertension[J]. World J Gastroenterol, 2016, 22(9):2725-2735. doi:10.3748/wjg.v22.i9.2725 URL
[3]	Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models[J]. Hepatol Int, 2018, 12(Suppl 1):1-10.
[4]	Garcia-Tsao G. The use of nonselective beta blockers for treatment of portal hypertension[J]. Gastroenterol Hepatol, 2017, 13(10):617-619.
[5]	Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 annual data report: liver[J]. Am J Transplant, 2017, 17(Suppl 1):174-251. doi:10.1111/ajt.14126 URL
[6]	Iwatsuki S, Starzl TE, Todo S, et al. Liver transplantation in the treatment of bleeding esophageal varices[J]. Surgery, 1988, 104(4):697-705.
[7]	Wood RP, Shaw BW Jr, Rikkers LF. Liver transplantation for variceal hemorrhage[J]. Surg Clin North Am, 1990, 70(2):449-461. doi:10.1016/S0039-6109(16)45091-7 URL
[8]	Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124(1):91-96. doi:10.1053/gast.2003.50016 URL
[9]	Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant wai-ting list[J]. N Engl J Med, 2008, 359(10):1018-1026. doi:10.1056/NEJMoa0801209 URL
[10]	Mahmud N. Selection for liver transplantation: indications and evaluation[J]. Curr Hepatol Rep, 2020:1-10.
[11]	Martin P, Dimartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3):1144-1165. pmid:24716201
[12]	Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis[J]. Liver Int, 2012, 32(9):1407-1414. doi:10.1111/j.1478-3231.2012.02830.x URL
[13]	D'amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995, 22(1):332-354.
[14]	Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J]. Am J Gastroenterol, 2007, 102(9):2086-2102. pmid:17727436
[15]	Zocco MA, di Stasio E, de Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol, 2009, 51(4):682-689. doi:10.1016/j.jhep.2009.03.013 URL
[16]	徐骁, 郭海军, 李望遥. 肝移植时代门静脉高压症的治疗选择[J]. 中华消化外科杂志, 2018, 17(10):992-996.
[17]	Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management[J]. Mayo Clin Proc, 2019, 94(4):714-726. doi:S0025-6196(18)31008-5pmid:30947834
[18]	Snyder P, Ali R, Poles M, et al. Portal hypertensive gastropathy with a focus on management[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(9):1207-1216. doi:10.1586/17474124.2015.1059275 URL
[19]	Akatsu T, Yoshida M, Kawachi S, et al. Consequences of living-donor liver transplantation for upper gastrointestinal lesions: high incidence of reflux esophagitis[J]. Dig Dis Sci, 2006, 51(11):2018-2022. doi:10.1007/s10620-006-9362-3 URL
[20]	Wijdicks EF. Hepatic encephalopathy[J]. N Engl J Med, 2016, 375(17):1660-1670. doi:10.1056/NEJMra1600561 URL
[21]	Fichet J, Mercier E, Genée O, et al. Prognosis and 1-year mortality of intensive care unit patients with severe he-patic encephalopathy[J]. J Crit Care, 2009, 24(3):364-370. doi:10.1016/j.jcrc.2009.01.008 URL
[22]	Lucidi C, Ginanni Corradini S, Abraldes JG, et al. He-patic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: evidence by means of 2 independent cohorts[J]. Liver Transpl, 2016, 22(10):1333-1342. doi:10.1002/lt.24517 URL
[23]	Bernal W, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure? a single centre expe-rience of 3300 patients[J]. J Hepatol, 2013, 59(1):74-80. doi:10.1016/j.jhep.2013.02.010 URL
[24]	Hopp AE, Dirks M, Petrusch C, et al. Hepatic encephalopathy is reversible in the long term after liver transplantation[J]. Liver Transpl, 2019, 25(11):1661-1672. doi:10.1002/lt.25626 URL
[25]	Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites[J]. World J Gastroenterol, 2019, 25(28):3738-3752. doi:10.3748/wjg.v25.i28.3738 URL
[26]	Adebayo D, Neong SF, Wong F. Refractory ascites in li-ver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1):40-47. doi:10.1038/s41395-018-0185-6 URL
[27]	Arroyo V, Gines P, Gerbes AL, et al. Definition and dia-gnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club[J]. Hepatology, 1996, 23(1):164-176. pmid:8550036
[28]	Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006, 4(11):1385-1394. doi:10.1016/j.cgh.2006.08.007 URL
[29]	Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites[J]. N Engl J Med, 2004, 350(16):1646-1654. doi:10.1056/NEJMra035021 URL
[30]	Moreau R, Delegue P, Pessione F, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites[J]. Liver Int, 2004, 24(5):457-464. doi:10.1111/j.1478-3231.2004.0991.x URL
[31]	Somsouk M, Kornfield R, Vittinghoff E, et al. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk[J]. Liver Transpl, 2011, 17(2):129-136. doi:10.1002/lt.22218 URL
[32]	Adebayo D, Neong SF, Wong F. Ascites and hepatorenal syndrome[J]. Clin Liver Dis, 2019, 23(4):659-682. doi:10.1016/j.cld.2019.06.002 URL

肝硬化门静脉高压症的肝移植治疗

Liver transplantation in treatment of cirrhotic portal hypertension

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表1

参考文献32

相关文章15

编辑推荐

Metrics

本文评价

[1]	Chang Jessica, 陈旭晓, 陈拥军.脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.
[2]	杨文康, 张俊, 王淑秋, 祥巴央宗, 杨翠萍.我国云南香格里拉地区104例肝硬化患者的病因及临床特征分析[J]. 诊断学理论与实践, 2022, 21(06): 730-734.
[3]	张梦茵, 陈平, 袁晓琴, 蔡波尔, 吴云林.内镜下组织黏合剂联合硬化剂注射治疗胃静脉曲张临床研究及随访[J]. 外科理论与实践, 2022, 27(05): 443-447.
[4]	杨雪, 刘锦, 王铮, 陶杰, 郝杰, 李宇, 孙昊.他克莫司降低肝移植病人ERCP术后胰腺炎发生的临床观察[J]. 外科理论与实践, 2022, 27(03): 253-255.
[5]	吴浩翔, 吕子成, 侯宇宸, 张子杰, 乔子耘, 冯浩, 夏强.儿童肝移植中他克莫司浓度个体内变异[J]. 外科理论与实践, 2022, 27(02): 145-151.
[6]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦.术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[7]	黄纪伟, 邱国腾, 曾勇.肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[8]	冯浩, 吕子成, 夏强.肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[9]	周香雪, 黄海威.肝豆状核变性影像学研究进展[J]. 内科理论与实践, 2021, 16(05): 308-314.
[10]	赵英妹, 聂红明, 张珏, 黄燕.肝硬化患者凝血五项的测定及其临床意义[J]. 诊断学理论与实践, 2021, 20(05): 480-483.
[11]	张斌, 吴志勇.门静脉高压症食管胃底静脉曲张出血的个体化治疗和手术方式选择[J]. 外科理论与实践, 2021, 26(03): 185-188.
[12]	孙隆慈, 张斌.门静脉海绵样变致食管胃底静脉曲张的手术治疗(附1例报告)[J]. 外科理论与实践, 2021, 26(03): 226-230.
[13]	陈炜, 卜俊峰.肝功能评估方式及在门静脉高压症围术期的应用[J]. 外科理论与实践, 2021, 26(03): 212-216.
[14]	杨涛, 阴继凯, 鲁建国.腹腔镜技术在门静脉高压症外科手术中的前景[J]. 外科理论与实践, 2021, 26(03): 217-220.
[15]	崔然, 叶伦河, 王旭菁, 王永坤, 张琪祺, 王恺京, 王明, 戴陈新, 杨鹿笛, 董春秀, 陈波.腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症的近期临床结果[J]. 外科理论与实践, 2021, 26(03): 221-225.